MAIA Biotechnology, Inc.
Close on Oct 19, 2026
- Market cap
- $65.05M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2023 Ended Sep 30, 2023 | Nov 7, 2023 | Before market open | – | $-0.36 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 8, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 8, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 24, 2023 | After market close | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 9, 2022 | After market close | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 22, 2022 | Before market open | – | – | – |
Press releases
Announcements MAIA Biotechnology filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
Material agreement · Other events · EX-99.3 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity
Other events · EX-99.2 to Form 8-K
Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biotechnology Announces $1.51 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals
Other events · EX-99.1 to Form 8-K
Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
Other events · EX-99.3 to Form 8-K
Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
Other events · EX-99.1 to Form 8-K
Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
Other events · EX-99.1 to Form 8-K
Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Biotechnology Announces $736,600 Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets
Other events · EX-99.1 to Form 8-K
Biotechnology Announces $2.25 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy
Other events · EX-99.1 to Form 8-K
Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
Other events · EX-99.1 to Form 8-K
Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
Other events · EX-99.1 to Form 8-K
Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
Other events · EX-99.1 to Form 8-K
Biotechnology Announces Master Clinical Supply Agreement with
Other events · EX-99.3 to Form 8-K